Table 2.
Association of Preemptive Morphine Sedation During Therapeutic Hypothermia with Magnetic Resonance Spectroscopy Biomarkers and Neurodevelopmental Outcomes
| Outcome | Sedation | n | Mean ± SD | Unadjusted |
Adjusteda |
||
|---|---|---|---|---|---|---|---|
| Mean (95% CI) | p | Mean (95% CI) | p | ||||
| Bayley cognitive | No | 17 | 99.0 ± 12.5 | 0 | 0.43 | 0 | 0.71 |
| Yes | 115 | 94.8 ± 21.1 | −4.2 (−14.6 to 6.2) | −1.9 (−11.7 to 7.9) | |||
| Bayley language | No | 15 | 93.1 ± 8.0 | 0 | 0.44 | 0 | 0.68 |
| Yes | 111 | 88.6 ± 22.3 | −4.5 (−16.1 to 7.0) | −2.2 (−12.8 to 8.4) | |||
| Bayley motor | No | 17 | 93.6 ± 10.1 | 0 | 0.71 | 0 | 0.97 |
| Yes | 115 | 91.5 ± 22.5 | −2.0 (−13.0 to 8.9) | 0.2 (−9.9 to 10.2) | |||
| NAA | No | 10 | 6.85 ± 0.85 | 0 | 0.52 | 0 | 0.97 |
| Yes | 61 | 6.54 ± 1.49 | −0.31 (−1.28 to 0.65) | −0.02 (−0.91 to 0.95) | |||
| NAA/Cr | No | 23 | 1.61 ± 0.29 | 0 | 0.08 | 0 | 0.21 |
| Yes | 119 | 1.50 ± 0.27 | −0.11 (−0.23 to 0.01) | −0.08 (−0.21 to 0.05) | |||
| Outcome | Sedation | n | Median [IQR] | Unadjusted |
Adjusteda |
||
|---|---|---|---|---|---|---|---|
| Ratio (95% CI) | p | Ratio (95% CI) | p | ||||
| Lac/NAA | No |
23 |
0.13 [0.11 to 0.18] |
1 |
0.09 |
1 |
0.20 |
| Yes | 119 | 0.16 [0.12 to 0.21] | 1.30 (0.96 to 1.76) | 1.22 (0.90 to 1.65) | |||
| Outcome | Sedation | n | n (%) | Unadjusted |
Adjusteda |
||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | ||||
| Adverse neuro |
No |
17 |
0 (0) |
1 |
0.05 |
1 |
0.11 |
| Outcome | Yes | 125 | 26 (21) | 6.15 (0.99 to ∞) | 4.94 (0.72 to ∞) | ||
a
Adjusted for PPHN, hypotension, and encephalopathy severity score at admission.
CI, confidence interval; IQR, interquartile range; NAA, N-acetylaspartate; OR, odds ratio; PPHN, persistent pulmonary hypertension of the newborn.